

Corporate Action Notice

June 3, 2015

Ratio Change

BiolineRX

DR CUSIP: 09071M106 / **ISIN:** US09071M1062

DR Ticker Symbol: BLRX

Ratio: (DR: Underlying Share): 1:10

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATES FOR THIS CORPORATE ACTION:

Effective Date:	June 8, 2015
Old Ratio:	1 DR : 10 ORDs
New Ratio:	1 DR : 1 ORD

BNY Mellon has been advised that BiolineRX (the "Company") announced a 1 for 10 reverse stock split on its ordinary shares in the local market. As a result BiolineRX has instructed BNY Mellon, as Depositary to effect a ratio change on the DR program from one (1) DR representing ten (10) Ordinary shares to one (1) DR representing one (1) Ordinary Share.

No exchange of DR certificate(s) is required. Any outstanding DR certificate(s) will automatically be deemed to conform to the new parameters of the DR facility. DR holders need not take any action in regards to this ratio change. The CUSIP #'s will remain the same.

NOTE: A ratio change may impact the fees payable by DR investors

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis
Richard J Maehr
+ 1 212 815 2267
addrdesk@bnymellon.com

LONDON

Damon Rowan
Vice President
+ 44 207 163 7511
damon.rowan@bnymellon.com

HONG KONG

Herston Powers
Vice President
+ 852 2 840 9868
herston.powers@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may also transact with affiliates and dealers. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities. The conversion rate reflects a foreign currency ("FX") transaction ("FX Trade") executed by BNY Mellon as principal counterparty and not as agent, fiduciary or broker. BNY Mellon has no obligation to obtain the "best price" for any FX Trade. BNY Mellon earns revenue on the FX Trade based on, among other things, the difference between the rate it assigns to the FX Trade and the rate that it pays and receives for purchases and sales of currencies when engaging in any offsetting trades for its own account. The decisions BNY Mellon makes on when and how to enter into any offsetting trades, as well as other factors (including but not limited to liquidity and market volatility), affect the revenue BNY Mellon earns on FX Trades.



BNY MELLON